Search results
Showing 1291 to 1305 of 2006 results for nice guidelines
Prevena incision management system for closed surgical incisions (MIB173)
NICE has developed a medtech innovation briefing (MIB) on Prevena incision management system for closed surgical incisions .
Evidence-based recommendations on lutetium (177Lu) oxodotreotide (Lutathera) for treating unresectable or metastatic neuroendocrine tumours in adults.
"item":{"@id":"/get-involved/our-committees","name":"Our committees"}}]} Your role as a NICE committee member From GPs, nurses and...
"item":{"@id":"/get-involved/our-committees","name":"Our committees"}}]} Your role as a NICE committee member From GPs, nurses and...
Our recommendations on the use of highly specialised technologies are made by an independent advisory committee
Our recommendations on the use of highly specialised technologies are made by an independent advisory committee
Evidence-based recommendations on tocilizumab (RoActemra) for treating giant cell arteritis in adults.
National Early Warning Score systems that alert to deteriorating adult patients in hospital (MIB205)
NICE has developed a medtech innovation briefing (MIB) on National Early Warning Score systems that alert to deteriorating adult patients in hospital .
Early value assessment (EVA) guidance on artificial intelligence (AI) technologies to aid opportunistic detection of vertebral fragility fractures.
November 2025: We have withdrawn this quality standard following the launch of new NICE guidelines on suspected sepsis in people aged 16 or over, suspected sepsis in under 16s and suspected sepsis in pregnant or recently pregnant people. This quality standard is now partially replaced by NICE's quality standard on suspected sepsis in over 16s. Quality standards for sepsis in people under 16 and for people who are or have recently been pregnant will publish when paediatric and maternity early warning score tools are reviewed for the next update to the NICE guidelines in 2026. For any queries, please contact qualitystandards@nice.org.uk.
Setmelanotide for treating obesity caused by LEPR or POMC deficiency (HST21)
Evidence-based recommendations on setmelanotide (Imcivree) for treating obesity caused by LEPR or POMC deficiency in people 6 years and over.
Evidence-based recommendations on romosozumab (EVENITY) for severe osteoporosis in people after menopause who are at high risk of fracture.
Early value assessment (EVA) guidance on point-of-care tests for urinary tract infections to improve antimicrobial prescribing.
The Airsonett temperature-controlled laminar airflow device for persistent allergic asthma (MIB8)
NICE has developed a Medtech Innovation Briefing (MIB) on the Airsonett temperature-controlled laminar airflow device for persistent allergic asthma
Healthcare-associated infections: prevention and control (PH36)
This quality improvement guide was produced by NICE, in partnership with Public Health England (PHE). Its aim is twofold: to reduce the risk of harm from healthcare-associated infections for patients, staff and visitors; and to reduce the costs associated with preventable infection.
Show all sections
Sections for PH36
- Overview
- Introduction
- Quality improvement statement 1: Board-level leadership to prevent HCAIs
- Quality improvement statement 2: Be a learning organisation
- Quality improvement statement 3: HCAI surveillance
- Quality improvement statement 4: Workforce capacity and capability
- Quality improvement statement 5: Environmental cleanliness
- Quality improvement statement 6: Multi-agency working to reduce HCAIs